Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection

• Status: Terminated
• Trial end date: 2020-12-15
• Target enrollment: 0
• Participant gender: All

Summary

The symptoms of respiratory distress caused by COVID-19 may be reduced by drugs combining anti-inflammatory and antiviral effects. This dual effect may simultaneously protect severely-ill patients and reduce the viral load, therefore limiting virus dissemination We want to demonstrate the superiority of naproxen (anti-inflamatory drug) treatment addition to standard of care compared to standard of care in term of 30-day mortality.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Naproxen

Criteria

Inclusion Criteria:

• COVID-19 infected patient

• Age 18 years or older

• Presence of pneumonia

• PaO2/FiO2 < 300 mm Hg or SpO2 < 93% in air ambient or need to supplementary oxygen administration in order to maintain SpO2 range in [94-98%] or lung infiltrates > 50%

• Medical insurance

Exclusion Criteria:

• Presence of do-not-resuscitate order

• Pregnancy

• Prisoners

• Known Naproxen allergy or intolerance

• Severe renal failure